Pentixapharm Holding AG
PTP
Company Profile
Business description
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
Contact
Robert-Rossle-Street 10
Berlin13125
DEUT: +49 3094892600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
64
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.70 | 7.70 | 0.09% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,655.30 | 105.26 | -0.21% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,388.44 | 40.53 | 0.15% |
| NASDAQ | 26,402.48 | 314.28 | 1.20% |
| Nikkei 225 | 63,272.11 | 529.54 | 0.84% |
| NZX 50 Index | 13,063.06 | 17.27 | -0.13% |
| S&P 500 | 7,446.28 | 45.32 | 0.61% |
| S&P/ASX 200 | 8,630.40 | 0.60 | -0.01% |
| SSE Composite Index | 4,242.57 | 28.08 | 0.67% |